A new substance, Benzrnalacene, was tested to determine whether it had hypoeholesteremic effect in normotensive, hypertensive and hypercholesteremic patients. It proved effective. But after 4 months' treatment liver function began to deteriorate. It is strongly urged that drugs which interfere with cholesterol synthesis in the body be studied most carefully for long periods before widespread clinical trials to prevent atherosclerosis are attempted.
ONE approach to the problem of prevention of atherosclerosis is the prevention of hyperlipemia and, more specifically, hypercholesteremia. Diet, nicotinic acid, and /3-sitosterol have been most commonly used for this purpose, and with some success, in reducing hyperlipemia. Recently, attempts have been made to suppress the synthesis of cholesterol in the hope that hypercholestereinia would be abolished and yet leave hornional syntheses and other metabolic functions of! steroids undisturbed. Feeding of delta-4-cholestenone suppressed hepatic cholesterol synthesis and reduced the serum cholesterol level, but caused marked adrenal hypertrophy alas well.1 A number of other agents have I)eeni tried with limited success and these heave been well reviewed by Kritchevsky2 and by Curran and Azarnoff.3 It has been shown that probenecid inhibits acetate activation of coenzyme A as the latter is involved in glycine conjugation with paminobenzoic acid. 4 Recently a compound has been synthesized that is 10 times more active than probenecid in its ability to inhiibit renal tubular secretion of penicillin. Correspondingly, it is more active in inhibiting incorporation of acetate and mevalonic acid into the synthesis of cholesterol in vitro. 5 This substance, Benzmalacene,* is a derivative of the monamide of maleic acid, having On the basis of these results we have studied Benzmalacene to determine its effects ol the serum cholesterol levels in 6 women and 13 men. Of the 19 patients, 10 had severe essential hypertension and 2 presented the syndrome of malignant hypertension: 7 other patients exhibited hypercholesteremia or hyperlipemia. All hypertensive patients were on free diets at home except for moderate salt restriction. Five of the 7 patients with abnormal serum lipid patterns had followed a carefully controlled diet, containing 50 to 80 Gm. of fat as vegetable oil, for periods ranging from 6 to 18 months; the remaining 2 patients (cases 16 and 17) had eaten freely chosen foods.
The dose of Benzmalacene was 250 mg. given by mouth 2 to 4 times daily after neals; the average daily dose was 750 mg. Clearly Benzmalacene can lower blood cholesterol levels for long periods without marked changes in body weight but liver function as measured by dye retention slowly but progressively becomes disturbed. While slow in onset, the liver dysfunction could become serious, therefore after a maximum of 4 months the drug was discontinued. We were unable in this period of time to detect other cognate changes in the patients.
RESULTS

Administration of Benzmalacene to
Gastric burning, pain, nausea, and diarrhea occurred in some patients requiring discontinuance of the drug; in others, these symptoms were hardly noticeable.
In 2 patients the serum lipid pattern was studied by Dr. Helen Brown. It was shown that approximately 5 months after beginning the drug the total cholesterol had fallen significantly but concurrently the triglycerides had risen, along with the ratio of free to total cholesterol. But the ratio of total cholesterol to phosphatide fell sharply. These changes were profound. Without further studies we can no more than guess their significance. For our current purpose, the change underscores the capacity of drugs such as PAGE, SCHNECKLOT11
Benzmalacene to alter the lipid economy of the body for better or for worse.
We believe that drugs such as this one should be carefully studied in animals for long periods and in a few select patients before they are used in the hopes of preventing atherosclerosis. 
